Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

Das, S, Vital, EM, Horton, S et al. (6 more authors) (2014) Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Annals of the Rheumatic Diseases, 73 (5). 909 - 912. ISSN 0003-4967

Abstract

Metadata

Authors/Creators:
  • Das, S
  • Vital, EM
  • Horton, S
  • Bryer, D
  • El-Sherbiny, Y
  • Rawstron, AC
  • Ponchel, F
  • Emery, P
  • Buch, MH
Dates:
  • Published: May 2014
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Rheumatology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 15 Aug 2014 11:09
Last Modified: 08 Nov 2016 20:13
Published Version: http://dx.doi.org/10.1136/annrheumdis-2013-204417
Status: Published
Publisher: BMJ Publishing Group
Identification Number: https://doi.org/10.1136/annrheumdis-2013-204417
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics